Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck's Zaire Ebolavirus Vaccine Registered in Four African Countries

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2020 | 12:29pm EST

By Stephen Nakrosis

Merck & Co. Inc. said Friday its Ervebo vaccine, which is indicated for the prevention of disease caused by Zaire ebolavirus, was approved in four African countries.

Merck said the vaccine was registered in the Democratic Republic of the Congo, Burundi, Ghana and Zambia.

Merck had previously said it is working to begin manufacturing licensed doses and expects them to be available staring around the third quarter of 2020. Merck is working with the U.S. government, WHO, UNICEF, and others to plan for how "licensed doses will support future public health preparedness and response efforts against Zaire ebolavirus disease."

Ervebo doesn't protect against other species of Ebolavirus or Marburgvirus, Merck said.

The vaccine "was granted a conditional marketing authorization by the European Commission on November 11, 2019 and approved by the U.S. Food and Drug Administration on Dec. 20, 2019," the company said.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY -0.39% 82.1288 Delayed Quote.-9.33%
MERCK KGAA 1.50% 125.35 Delayed Quote.17.23%
PROCTER & GAMBLE COMPANY 1.25% 126.44 Delayed Quote.-0.02%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
10:43aMerck KGaA sells allergy unit to Dermapharm, keeps autoinjector project
RE
10:41aMerck KGaA Sells Allergy Business to Dermapharm
DJ
08:46aMERCK AND : Receives Complete Response Letter from the US FDA for Supplemental B..
AQ
08:39aImmutep Says Interim Phase II TACTI-002 Data Positive
DJ
02/18MERCK : Receives Complete Response Letter from the US FDA for Supplemental Biolo..
BU
02/18Marriott Names Jim Scholefield Chief Information, Digital Officer
DJ
02/18Merck KGaA Chosen to Produce Liquid Biopsy Kits
DJ
02/17MERCK AND : - ERVEBO Now Registered in Four African Countries Within 90 Days of ..
AQ
02/14Merck's Zaire Ebolavirus Vaccine Registered in Four African Countries
DJ
02/14MERCK AND : ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African C..
BU
More news
Financials (USD)
Sales 2020 49 660 M
EBIT 2020 17 752 M
Net income 2020 12 422 M
Debt 2020 17 799 M
Yield 2020 2,93%
P/E ratio 2020 16,9x
P/E ratio 2021 16,5x
EV / Sales2020 4,59x
EV / Sales2021 4,28x
Capitalization 210 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 98,11  $
Last Close Price 82,46  $
Spread / Highest target 29,8%
Spread / Average Target 19,0%
Spread / Lowest Target 9,14%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-9.33%209 942
JOHNSON & JOHNSON2.92%392 517
ROCHE HOLDING AG8.47%299 201
NOVARTIS4.05%220 283
PFIZER-6.81%200 999
NOVO NORDISK AS12.78%150 539